What changed
Hugel said more than 50% of its strategic U.S. accounts had reached the "account activation" stage by early November. That stage means negotiating a supply agreement or training medical staff before a product goes on the shelf. In mid-September the share was about 30%. So it added roughly 20 points in six weeks.
The strategic accounts are large U.S. aesthetic chains that Hugel is selling to through its own sales force, not through a distributor.
The money side is uglier. Hugel's third-quarter operating profit dropped 61.8% from a year earlier, to KRW 18.1 billion. The cause was the switch in model. Until recently, Hugel booked a sale the moment it shipped Letybo to its U.S. distributor, Benev. In September, about a year ahead of schedule, Hugel ended that agreement, bought back the inventory sitting in Benev's warehouse and reversed the sales it had booked on it. The buyback was larger than the new sales in the quarter, so North and South American toxin sales came in at negative KRW 200 million.
Selling, general and administrative expenses rose 60% year over year. Hugel hired about 40 people in the United States and spent more on marketing.
What it means for practices (analysis)
If you are a chain buying toxin, this is the part to watch. Hugel is trying to set its own price. Securities analysts estimate its average selling price under direct sales will run more than twice what it got through distributors. That gap is the reason for the pain on the income statement. A company that sells direct also has to carry the sales staff, the training and the inventory risk that a distributor used to carry.
For a practice, the near-term effect is more sales reps calling on you and more activation work, such as contract terms and staff training, landing on your calendar. Expect pricing to be negotiated rather than posted. The article does not say what discounts or terms Hugel is offering the accounts it has signed, so I would not assume any particular number until you see the paper.
The comparison Hugel is drawing is with Daewoong Pharmaceutical's Nabota, sold in the U.S. as Jeuveau. Daewoong reported on November 4 that Nabota sales reached a quarterly record of KRW 116.3 billion, with exports at KRW 106.8 billion, up 127.9%. Read that number with care. Daewoong books revenue when it ships to Evolus, its U.S. partner, not when clinics inject product. Analysts say Evolus bought an unusually large volume ahead of U.S. pharmaceutical tariffs in September 2026, and Daewoong itself blamed concentrated U.S. shipments. Evolus's warehouse is now stocked, so the article expects shipments to the U.S. could fall in the fourth quarter.
So the two Korean companies look strong or weak depending on which number you read. Shipments to a distributor are not the same as a product moving off a clinic shelf.
Evolus had a 14% share of the U.S. botulinum toxin market in the first three quarters of 2025, according to the report. Hugel's target is to reach that same share by 2030.
What owners can do now
Ask your current toxin supplier and any new one the same question: what is the price per unit on the purchase order, and what is the price after rebates, training fees and returns. Hugel's direct model means the rep is the one who writes that number. Get it in writing before your next order.
If Letybo is on your radar, ask Hugel's sales team for its activation requirements and the timeline for your account. The report says the company has entered talks with the large chains it targeted, so a smaller independent practice is not the target of this push and should expect the process to be slower.
Check your inventory exposure before you sign. Hugel's own third-quarter numbers show how fast a product can flip from booked sales to a buyback. A practice that stocks a large lot on a single quarter's promotion carries the same risk in miniature.
What we don't know yet
The report does not say how many strategic accounts Hugel is targeting in total, so "more than half" is a share of an unstated list. It does not give the actual U.S. prices Hugel is charging, only the analysts' estimate of direct-model pricing. It also does not say how many activated accounts have signed a supply agreement versus only started training.
An industry source said the two products' real competitiveness can be judged only in the second half of 2027, when Hugel handles all U.S. sales itself. That is the date to watch. Until then, every number on both sides is a shipment or a sign-up, not a sale to a patient.
Business information, not medical or legal advice. Verify regulatory status at FDA.gov.
